PADI4 and COVID-19: Currently, new generation of NE inhibitors (Lonodelestat, Alvelestat, CHF6333 and Elafin) have entered clinical trials, albeit neither NE nor PAD4 inhibitors are currently tested in clinical trials investigating COVID-19.